Skip to content

A randomized, open-label, parallel-controlled clinical study on the efficacy and safety of Guben Kechuan Granules in treating cough and wheezing symptoms in patients with pulmonary tuberculosis and lung-kidney qi deficiency syndrome

A randomized, open-label, parallel-controlled clinical study on the efficacy and safety of Guben Kechuan Granules in treating cough and wheezing symptoms in patients with pulmonary tuberculosis and lung-kidney qi deficiency syndrome

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104717
Enrollment
Unknown
Registered
2025-06-23
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary tuberculosis

Interventions

Conventional treatment + Guben Kechuan Granules:On the basis of anti-tuberculosis treatment, Guben Kechuan Granules were added,Take orally, 1 bag each time, 3 times a day
In this research protocol, continuous medication should be administered for no less than 2 weeks during the treatment period. During the follow-up period (the 4th and 12th weeks after the last adminis
Conventional treatment:Anti-tuberculosis treatment

Sponsors

Wuhan Jinyintan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria (1) The subjects voluntarily participated in the trial and signed the informed consent form; Age: 18 to 70 years old (including 18 and 70 years old); (3) It meets the criteria of "Diagnosis of Pulmonary Tuberculosis" (WS288-2017), and is a confirmed case and a clinically diagnosed case. Cough and/or wheezing for 2 weeks or more, with a cough symptom score of >= 2; (4) No mental illness.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1) Combined with severe lung diseases, such as severe COPD, advanced lung cancer, etc. (2) Those who suffer from severe hypertension, heart failure, arrhythmia, diabetes, primary heart, liver, kidney, blood, and neurological symptoms that are not well controlled; (3) Those with severe immunodeficiency diseases, such as those who have been using immunosuppressants for a long time, those who have been using biological agents, and those with a CD4 cell count less than 200 cells /µL; (4) Allergic to the ingredients of Guben Kechuan Granules; (5) Pregnant or lactating women, men and women who plan to give birth in the near future; (6) Those considered unsuitable for inclusion in the group by the study;

Design outcomes

Primary

MeasureTime frame
Leicester Quality of Life Questionnaire;PF (pulmonary function);Cough Symptom Scorecard;

Countries

China

Contacts

Public ContactNieqi

Wuhan Jinyintan Hospital

103874586@qq.com+86 139 9567 6217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026